Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact ® Survey 2020.

Autor: Bueno APA; Cerner Enviza, An Oracle Company, Av. das Nações Unidas 14171 15º andar, Morumbi São Paulo/SP CEP 04794-000, Brazil., Clark O; Cerner Enviza, An Oracle Company, 2300 Oracle Wy, Austin, TX 78741, USA., Turnure M; Cerner Enviza, An Oracle Company, 2300 Oracle Wy, Austin, TX 78741, USA., Moreira ES; Cerner Enviza, An Oracle Company, Av. das Nações Unidas 14171 15º andar, Morumbi São Paulo/SP CEP 04794-000, Brazil., Chang J; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA., Hou N; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA., Li S; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA., Kim R; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA., Kearney M; Merck Healthcare KGaA, Frankfurter Strasse 250 Darmstadt, 64293, Germany., Kirker M; Pfizer Inc, 235 E 42nd St, New York, NY 10017, USA., Kanas G; Cerner Enviza, An Oracle Company, 2300 Oracle Wy, Austin, TX 78741, USA.
Jazyk: angličtina
Zdroj: Future oncology (London, England) [Future Oncol] 2024 Mar; Vol. 20 (10), pp. 613-622. Date of Electronic Publication: 2023 Jun 26.
DOI: 10.2217/fon-2022-1066
Abstrakt: Aim: This study assessed physician-reported treatment patterns for metastatic bladder cancer. Materials & methods: A total of 106 USA-based physicians were surveyed in 2020 using the CancerMPact ® online survey. Results: Among cisplatin-eligible patients, 86.1% received first-line (1L) platinum-containing chemotherapy, most commonly cisplatin plus gemcitabine, and 9.8% received immune checkpoint inhibitor monotherapy. Among cisplatin-ineligible patients, 46.5% received 1L platinum-containing chemotherapy, most commonly carboplatin plus gemcitabine and 46.2% received 1L immune checkpoint inhibitor therapy. Approximately 44% of patients who received 1L treatment received second-line (2L) therapy after progression. Conclusion: Platinum-containing chemotherapy was the most widely reported 1L treatment approach. A high proportion of patients received no 2L therapy. Validation in an updated dataset is warranted following the practice-changing approvals of avelumab 1L maintenance and additional 2L options.
Databáze: MEDLINE
Externí odkaz: